Gerresheimer AG (ETR:GXI)
Germany · Delayed Price · Currency is EUR | Market Cap | 899.42M -28.1% |
| Revenue (ttm) | 2.32B +16.6% |
| Net Income | -320.32M |
| EPS | -9.27 |
| Shares Out | 34.54M |
| PE Ratio | n/a |
| Forward PE | 11.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,375 |
| Open | 26.36 |
| Previous Close | 26.18 |
| Day's Range | 25.62 - 26.38 |
| 52-Week Range | 14.83 - 38.32 |
| Beta | 0.48 |
| Analysts | Hold |
| Price Target | 27.38 (+5.15%) |
| Earnings Date | Oct 15, 2026 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality manag... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for GXI stock is "Hold." The 12-month stock price target is €27.38, which is an increase of 5.15% from the latest price.
News
EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Gerresheimer AG Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distri...
EQS-DD: Gerresheimer AG: Active Ownership Opportunities SCS, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 07.09.2026 / 15:24 CET/CEST The issuer is solely responsi...
Gerresheimer AG Slides: FY 2026
Gerresheimer AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 1, 2026.
Gerresheimer Q1 Earnings Call Highlights
Gerresheimer ETR: GXI reported preliminary first-quarter 2026 results that showed modest revenue growth but lower earnings as the packaging and drug-delivery company prioritized cash preservation, red...
Gerresheimer AG Earnings Call Transcript: Q1 2026
Q1 2026 saw a strong focus on cash flow, with CapEx halved and inventory tightly managed, resulting in improved free cash flow despite lower EBITDA. Portfolio transformation is advancing with the sale of Centor and PPP, targeting leverage below 3x and operational improvements of EUR 50–70 million EBITDA by 2028.
Gerresheimer AG Slides: Q1 2026
Gerresheimer AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 27, 2026.
Gerresheimer AG Earnings release: Q1 2026
Gerresheimer AG released its Q1 2026 earnings on August 27, 2026, summarizing the period's financial results.
EQS-Adhoc: Gerresheimer AG: Uwe Röhrhoff Steps Down as Interim CEO
EQS-Ad-hoc: Gerresheimer AG / Key word(s): Personnel decisions / Executive Board/Significant contracts Gerresheimer AG: Uwe Röhrhoff Steps Down as Interim CEO 24-Aug-2026 / 19:29 CET/CEST Disclosure o...
EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Gerresheimer AG Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributi...
Germany's Gerresheimer to sell two units to Apax for $1.71 billion including debt
German drugs packaging firm Gerresheimer said on Wednesday it was selling two of its packaging units to private equity group Apax Funds for €1.5 billion ($1.71 billion) including debt.
Gerresheimer Q4 Earnings Call Highlights
Gerresheimer ETR: GXI said it has completed a broad review of compliance and accounting matters, published its audited 2025 annual report and is now focused on selling Centor, refinancing debt and imp...
Gerresheimer AG Earnings Call Transcript: Q4 2025
Restated and audited 2025 financials reflect extensive compliance work, with revenue at EUR 2.3 billion and flat organic growth. Margin improvement and cash generation are key 2026 priorities, supported by the GTO transformation and planned Centor sale and refinancing.
Gerresheimer AG Annual report: Q4 2025
Gerresheimer AG has published its Q4 2025 annual report on June 29, 2026.
Gerresheimer AG Annual report: Q4 2025
Gerresheimer AG has published its Q4 2025 annual report on June 29, 2026.
Gerresheimer AG Slides: Q4 2025
Gerresheimer AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on June 29, 2026.
Gerresheimer rejects takeover bid from US packing firm Silgan, say sources
German medical packaging maker Gerresheimer has rejected a takeover bid from its U.S. rival Silgan , three sources familiar with the situation told Reuters.
Gerresheimer delays 2025 results release to June, stock to be removed from SDAX
Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker ...
Gerresheimer AG Slides: Investor Presentation
Gerresheimer AG has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2025.
Gerresheimer appoints Uwe Röhrhoff as new interim CEO
Medical equipment maker Gerresheimer said on Tuesday it had appointed Uwe Röhrhoff as interim CEO, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO by mutual agreeme...
Gerresheimer finds 2024 revenue-recognition issues after external probe
Medical equipment maker Gerresheimer said it has obtained the initial findings from an investigation by an external law firm into the recognition of revenue and profit from bill-and-hold agreements in...
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and nine-month results were below expectations, with organic revenue and EBITDA declines driven by weak cosmetics and oral liquids markets. Guidance was revised downward, a transformation program was launched, and liquidity remains strong with no covenant breaches.
Gerresheimer AG Quarterly report: Q3 2025
Gerresheimer AG has published its Q3 2025 quarterly earnings report on October 10, 2025.
Gerresheimer AG Slides: Q3 2025
Gerresheimer AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 10, 2025.
Gerresheimer's shares fall 11% after another outlook cut
Shares in Gerresheimer fell 11% on Thursday, a day after the German packaging and medical equipment maker cut its 2025 guidance for the third time this year.
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and the first nine months of 2025 were below expectations, with organic revenue and EBITDA both declining year-over-year. Guidance was revised downward, with a projected organic revenue decline of -4% to -2% and an adjusted EBITDA margin of 18.5%-19%.